Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zymeworks Inc.
  6. News
  7. Summary
    ZYME   US98985Y1082


Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
9.540 USD   -0.42%
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium

11/22/2022 | 08:43am EST

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody.

Zanidatamab in combination with palbociclib and fulvestrant was well tolerated, with encouraging and durable antitumor activity in heavily pretreated patients with HER2-positive HR+ breast cancer. A poster with an updated and expanded data set will be presented at SABCS taking place in San Antonio, Texas and virtually on December 6-9, 2022.

Abstract highlights from the February 24, 2022 data cut: Thirty-four heavily pretreated patients with HER2-positive HR+ breast cancer were treated with zanidatamab in combination with palbociclib and fulvestrant.

The confirmed objective response rate was 34.5% and the disease control rate was 93.1% in 29 response-evaluable patients.

Ongoing durable responses were seen out to 14.9+ months, with 18 patients still on treatment at the time of the data cut.

Treatment-related adverse events were generally consistent with previous reports of zanidatamab and/or chemotherapy regimens, with the majority reported as Grade 1 or 2 in severity.

This regimen has the potential to be a chemotherapy-free treatment option in patients with HER2-positive HR+ metastatic breast cancer.

The abstract is available on the SABCS conference website. The spotlight poster presentation will be available on Friday, December 9 at 7:00 am Central Time (CT) to conference registrants on the SABCS conference website as well as to the general public on the Zymeworks website.

Title: Treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant

Lead Author: Santiago Escriva-de-Romani, MD, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona, Spain

Program Number: PD18-10

About Zanidatamab

Zanidatamab is a bispecific antibody, based on Zymeworks' Azymetric platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. This unique design results in multiple mechanisms of action including dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2 and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks' second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2-targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies.

Cautionary Note Regarding Forward-Looking Statements

This press release includes 'forward-looking statements' or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the potential therapeutic effects of zanidatamab and Zymeworks' other product candidates; Zymeworks' clinical development of its product candidates and enrollment in its clinical trials; anticipated clinical data presentations; expectations regarding future regulatory filings and the timing thereof, the commercial potential of technology platforms and product candidates and other information that is not historical information. When used herein, words such as 'plan', 'believe', 'expect', 'may', 'continue', 'anticipate', 'potential', 'will', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of the COVID-19 pandemic on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf, may be more severe and more prolonged than currently anticipated; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter into new partnerships or strategic collaborations and the factors described under 'Risk Factors' in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for its quarter ended September 30, 2022 (a copy of which may be obtained at www.sec.gov and www.sedar.com).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.


Jack Spinks

Tel: (604) 678-1388

Email: ir@zymeworks.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about ZYMEWORKS INC.
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas..
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perfor..
01/19Jazz Pharmaceuticals, Zymeworks Announce Positive Results From Phase 2 Trial of Esophag..
01/19Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Pha..
01/12Transcript : Zymeworks Inc. Presents at 41st Annual J.P. Morgan Healthcare Co..
01/04Zymeworks Updates on Cash Resources; Chief Medical Officer to Depart Amid Internal Reor..
01/04Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer
01/04Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
01/04HC Wainwright Adjusts Price Target on Zymeworks to $8 From $10, Maintains Neutral Ratin..
More news
Analyst Recommendations on ZYMEWORKS INC.
More recommendations
Financials (USD)
Sales 2022 241 M - -
Net income 2022 6,38 M - -
Net cash 2022 285 M - -
P/E ratio 2022 -38,0x
Yield 2022 -
Capitalization 614 M 614 M -
EV / Sales 2022 1,37x
EV / Sales 2023 5,63x
Nbr of Employees 286
Free-Float 86,5%
Duration : Period :
Zymeworks Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMEWORKS INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 11
Last Close Price 9,54 $
Average target price 13,45 $
Spread / Average Target 41,0%
EPS Revisions
Managers and Directors
Kenneth Harry Galbraith Chairman & Chief Executive Officer
Neil A. Klompas Chief Financial Officer
Christopher Astle Chief Financial Officer & Senior Vice President
Paul A. Moore Chief Scientific Officer
Lota S. Zoth Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.18.94%41 845
BIONTECH SE-4.37%34 142
BEIGENE, LTD.16.46%26 628